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Sorafenib is a multi-kinase inhibitor with antiangiogenic and antiproliferative activity. The activity of sorafenib in progressive hormone-
refractory prostate cancer (HRPC) patients was investigated in a phase II clinical study. Progressive HRPC patients received sorafenib
400mg bid p.o. continuously. Only patients with no prior chemotherapy, and either one-unidimensional measurable lesion according
to RECIST-criteria or increasing prostate-specific antigen (PSA) values reflecting a hormone-refractory situation, were eligible for
study entry. The primary study objective was the rate of progression-free survival of X12 weeks (PFS12). Secondary end points were
overall response, overall survival, and toxicity. Fifty-seven patients with PC were enrolled. Two patients had to be withdrawn from the
set of eligible patients. According to RECIST criteria, 4 patients out of 55 evaluable patients showed stable disease (SD). According to
PSA–response, we saw 11 patients with SD PSA and 2 patients were responders at 12 weeks (PFS12¼17/55¼31%). Among the
257 adverse events, 15 were considered drug related of maximum CTC-grade 3. Twenty-four serious adverse events occurred in 14
patients (14/55¼26%). Seven of them were determined to be drug related. No treatment-related death was observed. Sorafenib
has antitumour activity in HRPCP when evaluated for RECIST- and PSA-based response. Further investigation as a component of
combination regimens is necessary to evaluate its definite or overall clinical benefit for HRPCP.
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Sorafenib is an oral multi-kinase inhibitor that targets the Raf/
MEK/ERK signalling pathway and receptor tyrosine kinases
involved in tumour cell proliferation and angiogenesis (Wilhelm
et al, 2004). In vitro, sorafenib inhibited b-Raf and Raf-1 (c-Raf or
c-Raf-1), pro-angiogenic vascular endothelial growth factor
receptor, and platelet-derived growth factor receptor (Wilhelm
and Chien, 2002). Sorafenib prevented tumour cell proliferation in
vitro and tumour growth in human xenograft models (Wilhelm
et al, 2004).
Several tumour types have demonstrated mutations and over-
expression of factors inhibited by sorafenib. The B-Raf V600E
oncogene is present in 63% of melanomas (Ostman and Heldin,
2001), X50% of papillary thyroid carcinomas (Lima et al, 2004),
and 40% of sporadic colorectal cancers (Salvatore et al, 2004).
Although oncogenic Raf-1 mutations have not been detected in
human cancers (Kolch et al, 2002), activating k-Ras mutations
resulted in increased signalling through Raf-1 in 45% of patients
(Downward, 2003).
Prostate cancer is an angiogenic tumour type. Several studies
demonstrated expression of angiogenic factors in prostate
cancer, especially the concentration of the vascular endothelial
growth factor is higher in prostate cancer cells than in normal
prostate tissue (Mazzucchelli et al, 2000). Furthermore, elevated
level of basic fibroblast growth factor in the serum are evident.
The expression of another angiogenic factor, thymidin phosphor-
ylase, named platelet-derived endothelial cell growth factor,
demonstrates strong correlation to the vascular density and the
gleason-score in prostate cancer tissue and thus seems to be
important in terms of angiogenesis in prostate cancer (Kikuno
et al, 2003).
Single-agent sorafenib showed preliminary clinical efficacy in
several solid tumours (Awada et al, 2005; Clark et al, 2005; Moore
et al, 2005; Strumberg et al, 2005; Ratain et al, 2006). In metastatic
renal cell carcinoma patients, sorafenib significantly prolonged
progression-free survival (PFS) vs placebo in patients in whom
previous therapy failed (Escudier et al, 2007). Sorafenib was also
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sshown to be suitable for long-term administration because of its
good safety profile (Awada et al, 2005; Strumberg et al, 2005;
Abou-Alfa et al, 2006; Ratain et al, 2006).
Prostate cancer is the most common cancer in man. About 20%
of all new diagnosed prostate cancers present metastatic disease
and many others metastases despite treatment with surgery and
radiotherapy. Treatment of metastatic prostate cancer is palliative
in about 80% of men, primary androgen ablation is the treatment
of choice leading to symptomatic improvement and a reduction of
the PSA. Nevertheless, all patients finally get refractory to hormone
treatment. The therapeutic options then include symptomatic care
with analgetics, radiotherapy to the dominant sites of pain,
bisphosphonates, treatment with bone-seeking isotopes, low-dose
cortisone, and palliative chemotherapy. Chemotherapy can reduce
PSA levels and relieve pain in some patients, but intolerability is a
problem since many of the affected elderly patients exhibit other
serious medical problems. Quality of life and pain control
improved more frequently under therapy with mitoxantrone plus
prednisone than with prednisone alone in a randomised trial. But
this therapy has unfortunately no effect on survival (Tannock et al,
1996). Prolongation of survival has been shown recently for the
combination of docetaxel plus prednisone when compared to
mitoxantrone plus prednisone, which had been the previous
standard chemotherapy regimen since 1996. The median survival
benefit was 2.4 months in favour of docetaxel plus prednisone.
Response in terms of relief from pain, PSA decrease, and increase
in quality of life was also better in the docetaxel plus prednisone
treatment arm (Tannock et al, 2004). Nevertheless, both che-
motherapeutic interventions feature clinically relevant adverse
effects. Therefore, further improved treatment options for hormone-
refractory prostate cancer (HRPC) patients are urgently needed
since only two approved cytostatic agents exist, meaning rather
unsatisfying therapeutic impact for this therapeutic situation.
We conducted within the CESAR Central European Society for
Anticancer Research-EWIV, a phase II study in prostate cancer
patients with progressive disease (PD) while on hormone therapy,
therefore judged as hormone refractory. Sorafenib was selected as
study drug due to its antiangiogenic properties. Angiogenesis is a
fundamental event in the progress of tumour growth and
metastatic dissemination (Folkman, 1995). It was hypothesised
that angiogenesis is an important event in prostate cancer as it is in
other cancers and that therefore inhibition of angiogenesis should
have an influence on the tumour growth.
PATIENTS AND METHODS
Major eligibility criteria
Patients with HRPC eligible for this study were X18 years and had
an Eastern Cooperative Oncology Group performance status of p2
reflected by increasing PSA under antihormonal treatment with
GnRH-Analoga, antiandrogenes, and hormone withdrawal.
Hormone-refractory disease was defined as PSA increase of
X50% above nadir, on at least two successive occasions at least
1 month apart (Bubley et al, 1999) They had adequate bone
marrow function (haemoglobin 490gl
 1, absolute neutrophil
count X1.5 10
9l
 1, platelet count X100 10
9l
 1), adequate
liver function (total bilirubin p1.5 upper limit of normal (ULN),
activities of alanine amino transferase, and aspartate amino
transferase p2.5 ULN), and adequate renal function (serum
creatinine p1.5 ULN).
Written informed consent was obtained from all patients who
participated in the study, which was conducted according to the
Good Clinical Practice guidelines and the principles described in
the Declaration of Helsinki and which had been approved by the
Ethical Committees of participating sites.
Treatment
Study treatment consisted of daily 800mg sorafenib (400mg bid)
continuously given until the end of treatment. According to the
study protocol, treatment was discontinued due to progression
according to RECIST criteria, unacceptable drug-related toxicity,
death, or withdrawal of consent. Dose reduction to 400mg once
daily and treatment delays for clinically significant drug-related
haematologic or non-haematologic toxicities were allowed according
to the protocol. If further dose reductions were required, the patient
had to be withdrawn from the study. No other chemotherapy,
hormonal therapy, or experimental medications were permitted
while the patients were in the study.
Study design
This study was designed as a one-stage non-randomised non-
blinded, multicentre phase II trial to distinguish between the null
hypothesis H0: PFS12pp0¼0.20 vs the alternative H1: PFS12
Xp1¼0.40. Primary end point of the analysis was the rate of PFS
of at least 12 weeks (PFS12). Secondary end points were overall
response, overall survival, and safety. The primary end point
PFS12 is defined as ratio PFS12¼nTTP12/nTTP, where nTTP is the
number of patients eligible for the evaluation of progression up to
12 weeks, and nTTP12 is the number of patients eligible for the
evaluation who survived without PD (determined using RECIST-
and PSA-response criteria) for at least 12 weeks. The primary
efficacy variable PFS12 was planned to be analysed by a one-sided
exact binomial test for proportions of testing H0 at the level of
a¼0.10. The sample size was planned as of 55 patients to achieve a
power of 95%.
Evaluation of response
The primary objective of the trial was to define the efficacy of
sorafenib in HRPC patients. Tumour assessment was planned at
baseline, thereafter at 6 and 12 weeks and from then onwards every
8 weeks until PD or death.
We considered information until 12 weeks as sufficient for
RECIST, if for each target lesion at least one measurement was
available at 12 weeks after start of study drug. Patients with target
lesions at baseline were assessed by their target lesions. Patients
with no target lesions at baseline and who developed new lesions
or metastases during treatment until week 12 were classified as PD,
and PSA response was not used for the response assessment.
Response evaluation according to RECIST is based exclusively on
differences of the sum of the longest diameters of all target lesions
or on appearance of new target or non-target lesions (Therasse
et al, 2000).
Patients with target lesions at baseline and insufficient
information until 12 weeks were assessed by their PSA levels,
and their PSA response was determined. Patients without target
lesions at baseline and who did not show occurrence of new
lesions/new metastases were evaluated for response/progression
exclusively based on the presence and the development of the PSA
level since start of treatment.
Classification of PSA response/progression was performed as
follows: minimum requirement for PSA response was the existence
of a baseline PSA level PSA0 determined before start of treatment,
but not more than 2 weeks (Bubley et al, 1999) before.
Furthermore, for evaluability, at least one measurement had to
be available more than 1 week after the start of treatment.
Otherwise, the patient was not evaluable for response. For the
assignment of response, at least two further measurements were
required after start of treatment: one not earlier than 1 week after
start of treatment and the second at least 4 weeks after the first
value. Minimum requirement for stable disease (SD) was at least
one further measurement beside that of the basic value.
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sThe PSA-response evaluation further distinguished between the
magnitudes of the PSA level at baseline: patients with a baseline value
below 4ngml
 1 could only qualify for SD-PSA when remaining
below 4ngml
 1 or for PD-PSA when increasing from a value
p4ngml
 1 for more than 100% and increasing in the absolute value
by at least 5ngml
 1. Patients with a baseline value above 4ngml
 1
qualified for PSA response, SD-PSA, and PD-PSA according to the
criteria as follows: PSA response was attained when at least two
consecutive PSA levels were lower than the 50% level of the baseline
level, the first at minimum 1 week after the start of treatment and a
second value at least 4 weeks after that first value. Progression (PD)-
PSA was attained when no decrease of PSA occurred by 12 weeks,
that is: when X1 week after start of treatment at least one PSA level
is 100% higher than the baseline level (at least doubled between
baseline and this level) without intercurrent decrease of PSA (non-
decreasing course). Progression-PSA was also attained when a
decrease of PSA occurred by 12 weeks, in case, if at least one PSA
level is 100% higher than the nadir of PSA between baseline and this
level (not non-decreasing course), and the PSA level had increased
in the absolute value by at least 5ngml
 1. Stable disesae-PSA was
attained when neither the criteria for PD-PSA nor those for
response-PSA were fulfilled. According to this approach, the 12-
week response assessment was categorised as follows: response
(RECIST or PSA), SD (RECIST or PSA), PD (RECIST or PSA), and
early death. Early death was defined as death within 4 weeks after the
start of treatment. The response according to RECIST was always the
leading parameter for outcome.
Evaluation of toxicity
Adverse events were graded according to the National Cancer
Institute Common Terminology Criteria v3.0. A thorough safety
evaluation was performed with physical examination, analyses of
haematology, and biochemistry data in 2- and 4-week intervals
during treatment, respectively. For each symptom in each patient,
the maximum CTC grade was determined and counted according
to its annotated relation to treatment.
Statistical analysis
The characteristics of the study population and the outcome of the
primary and secondary end points were presented using descrip-
tive statistical methods. The exact binomial test was used to test
the one-sample, one-sided study hypothesis and Clopper–Pearson
confidence intervals (CIs) were calculated for frequencies.
Survival curves were calculated and graphically presented using
the Kaplan–Meier method for censored failure time data.
Confidence intervals were calculated for survival, using the
Greenwood formula and for medians, using the method of
Brookmeyer and Crowley.
Patient’s overall survival time was defined as the interval from
date of the first intake of study drug to death (from any cause) or
to last follow-up information for living patients (censored
observation).
Patient’s PFS was defined as the interval from date of the first
intake of study drug to the date of progression or death whichever
occurs first or to last follow-up information for living patients
(censored observation).
Statistical analyses were performed using the statistical packages
SAS for Windows Version 9.1 (SAS Institute Inc., Cary, NC, USA)
and R Version 2.1.1 (http://www.r-project.org).
RESULTS
Patient population and tumour characteristics
Between August 2004 and June 2005, a total of 57 patients were
recruited for treatment into the study by seven institutions. Owing
to study-relevant protocol deviations, two patients were excluded
from the efficacy set: one patient received chemotherapy before
study entry, and the other patient withdrew the consent before
start of the study. Median age of the 55 eligible patients was 70
years (range 52–82 years). Predominant ECOG performance status
was 1 (n¼29; 53%); 25 patients (46%) had status 0 and one (2%)
had status 2. The majority of the recruited patients (n¼41; 75%)
had both locally advanced and metastatic prostate cancer. All
patients were pretreated with antihormonal therapy, alone or in
different combinations: 17 patients had only antihormonal
therapy, 7 patients had antihormonal and radiotherapy, 7 patients
had antihormonal and surgical therapy, and 24 patients had
antihormonal, radio- and surgical therapy. Locally advanced
cancer was seen in seven patients (13%) and metastatic prostate
cancer in seven patients (13%). A summary of baseline patient and
tumour characteristics is displayed in Table 1. At baseline, a total
of 80 lesions (measurable and non-measurable) were recorded in
34 patients. The most frequent sites of distant metastases were
bone (43/80¼54%), lymph nodes (27/80¼34%), liver (4/
80¼5%), and lung (3/80¼4%). Twenty-one patients had combi-
nations of multiple lesions. The most frequent localisations were
bone (7/21¼33%), lymph nodes and bone (6/21¼29%), bone and
other (2/21¼10%), and multiple lymph nodes (2/21¼10%).
Primary efficacy
The categorisation according to RECIST resulted in no complete
responses, no partial responses, four patients with SD, four
patients with PD, and no early deaths. Fourty-seven patients could
not be evaluated with regard to RECIST because they did not have
measurable lesions. But all of those 47 patients were evaluable for
PSA response so that in a second step, PSA response was evaluated
as described in the section, evaluation of response.
The categorisation according to PSA showed 2 response-PSA, 11
SD-PSA, 21 PD-PSA, and 13 unknown (PSA). In the last case, PSA
was not assessable or there were insufficient data.
The outcome of the combined 12-week response was (see
Table 2): 2 responder PSA, 15 SD (4 RECIST and 11 PSA), 25 PD (4
RECIST and 21 PSA), no early death, and 13 unknown (PSA). On
the basis of five SD and two responders until 12 weeks, the PFS12
rate was 31% (17/55, 95% CI: 19–45%). This was sufficient to
reject the study null hypothesis H0: PFS12pp0¼0.20 with a
statistical significance of 0.05 (P¼0.037). Therefore, this phase II
Table 1 Patient and tumor characteristics (n¼55 evaluable patients)
Period of recruitment
October 2004–June 2005
Age (median, range)
70 (52–82) years
n %
Performance status
02 5 4 6
12 9 5 3
21 2
Tumour characteristics
Advanced 7 13
Metastatic 7 13
Advanced and metastatic 41 75
Grade of differentiation
G1 1 2
G2 17 31
G3 21 38
GX 16 29
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with respect to its primary objective of the PSF12 rate.
Survival
The median PFS was 8 weeks (95% CI: 6.4–14.7 weeks) and the 1
year PFS rate was 13% (95% CI: 6–28%). The Kaplan–Meier plot
for PFS in all patients is shown in Figure 1. At the time of analysis,
20 out of 55 patients (36%) had died, but the median survival time
was not reached yet. The 1-year overall survival rate was estimated
as 68% (95% CI: 56–82%). Figure 2 shows the Kaplan–Meier plot
for overall survival.
Drug safety
All 55 patients were evaluable for safety. In total, 257 different
adverse events (AEs) (referring to maximum CTC grade per
patient) were documented including 37 (14%) AEs with maximum
CTC grade 3. The AEs of CTC grade 4 were not observed. Table 3
shows maximal CTC grade per patient and symptom (only for
symptoms occurring in five or more patients) in relation to study
drug. Most frequently occurring drug-related AEs in the form of
clinical symptoms were fatigue, dermatological side effects, and
diarrhoea. Fifteen drug-related events of maximum CTC grade 3
were recorded in 15 patients (n¼4 definite, n¼6 probable, and
n¼5 possible). The most common drug-related AEs of maximum
CTC grade 3 were hypertension, rash in the form of acneiform
erruptions, desquamation of the skin, fatigue, and constipation.
Twenty-four serious adverse events occurred in 14 (26%) patients.
Seven serious adverse events in six patients were assessed to be
related to the study medication (n¼3 probable, n¼4 possible).
No treatment-related deaths occurred.
The most frequently occurring AEs based on clinical chemistries
of maximum CTC grade 3 were increase of the activities of alkaline
phosphatase (16%), ASAT (4%), hypophosphataemia (7%), lipase
(4%), hypocalcaemia (7%), PT-INR (4%), and anaemia (4%). In
only one patient, we saw decreased platelets of CTC grade 3 and a
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Figure 2 Probability of overall survival (n¼55).
Table 2 RECIST and PSA-based response evaluation
Response category RECIST PSA Total (n¼55)
Response 0 2 2
Stable disease (SD) 4 11 15
Progressive disease (PD) 4 21 25
Early death 0 0 0
Unknown —
a 13 13
aPSA response was evaluated only in patients of the RECIST-unknown category.
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Figure 1 Probability of PFS (n¼55).
Table 3 Severest adverse event per patient and relation to study drug (only symptoms occurring in five or more patients)
CTC-Symptom
Total
(drug related)
CTC grade 1
(drug related)
CTC grade 2
(drug related)
CTC grade 3
(drug related)
Fatigue 21 (13) 12 (5) 7 (6) 2 (2)
Pain 19 (3) 7 (3) 5 (0) 7 (0)
Skin 18 (16) 12 (11) 4 (3) 2 (2)
Diarrhoea 10 (10) 7 (7) 2 (2) 1 (1)
Neurologic 10 (6) 8 (6) 2 (0) 0
Hypertension 9 (9) 1 (1) 5 (5) 3 (3)
Infection 9 (0) 4 (0) 4 (0) 1 (0)
Constitutional symptoms 8 (5) 4 (3) 3 (2) 1 (0)
Gastrointestinal symptoms 8 (7) 7 (6) 1 (1) 0
Nausea 8 (6) 6 (5) 1 (1) 1 (0)
Anorexia 7 (4) 5 (4) 2 (0) 0
Constipation 7 (3) 4 (1) 1 (0) 2 (2)
Renal/Genitourinary symptoms 7 (0) 5 (0) 1 (0) 1 (0)
Hand-foot skin reaction 6 (6) 4 (4) 1 (1) 1 (1)
Weight loss 6 (0) 6 (0) 0 0
Hair loss 5 (5) 4 (4) 1 (1) 0
Mood alteration 5 (1) 4 (1) 1 (0) 0
Rash/desquamation 5 (5) 3 (3) 0 2 (2)
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toxicity occurred.
At least one dose reduction occurred in 9 out of 55 (16%)
evaluable patients. In four patients (7%), therapy was interrupted
for at least one time interval until treatment-related toxicity had
resolved to grade 2, except for skin toxicity, which had to resolve
to grades 0–1. Three patients received both dose reduction and
interruption of therapy.
DISCUSSION
This phase II trial was performed to evaluate the activity and safety
of sorafenib in patients with HRPC without prior systemic
chemotherapy. Fifteen out of 55 eligible patients showed SD (4
RECIST and 11 PSA) and two patients were PSA responder
(PFS12¼17/55¼31%). Therefore, this phase II trial concludes a
significant effect and demonstrates activity with respect to primary
end point PFS12. The treatment in the form of long-term
continuous oral administration exerted only mild toxicity.
Given the difficulties to assess tumour response and given the
uncertainty about the predictive value of response for clinical
benefit, a careful interpretation of the results is indicated.
Therefore, we conclude that sorafenib 400mg bid has only
moderate anticancer activity in HRPC patients. It has a mild-
toxicity profile and is well tolerated. Especially with regard to
quality of life, patients have a benefit, since conventional
chemotherapy for prostate cancer causes side effects and is
sometimes not well tolerated, often observed in elderly patients.
Nevertheless, single-agent therapy displays only limited impact.
Similar results with single-agent targeted therapy for prostate
cancer patients were demonstrated. In a phase II study with
sorafenib 400mg bid in 16 patients with HRPC, one patient had a
confirmed PSA-response and four patients had post-treatment PSA
decline without any other immediate therapy. Treatment was
generally well tolerated and according to the authors, the results
indicate a potential detrimental effect and a positive delayed effect
on PSA production and secretion (Chi et al, 2005).
Another phase II trial with pertuzumab, a humanised mono-
clonal antibody, was conducted for patients with HRPC in
progression after taxane therapy. Pertuzumab represents a new
class of targeted anticancer agents that inhibit human epidermal
growth factor receptor dimerisation. The human epidermal growth
factor receptor family of receptors dimerises and activates
intracellular signalling pathways, leading to cellular growth,
proliferation, and survival. Preclinical studies demonstrated that
inhibition of ligand-dependent heterodimerisation with pertuzumab
effectively inhibits tumour growth and diminishes mitogen-
activated protein kinase and phosphatidyl-inositol 3-kinase
activity in both androgen-dependent and -independent prostate
cancer xenograft models. In 30 assessable patients, no objective
responses were seen, but four patients had SD for at least 23 weeks
and one had SD for 36 weeks. The author underlined the clinical
benefit for the patients (Agus et al, 2007).
Since docetaxel has become the status of a standard therapy in
HRPC patients, there are efforts to improve the efficacy of
docetaxel-based chemotherapy for HRPC. This includes combining
docetaxel with other agents with novel mechanisms of action, such
as atrasentan (George et al, 2005), thalidomide (Dahut et al, 2004),
bevacizumab (Berry and Eisenberger, 2005), and DN-101 (Beer
et al, 2007). The combination of docetaxel plus sorafenib may
represent a contribution to these efforts on the basis that this
drug combination was tested within a phase I study and
showed clinical activity in patients with advanced, refractory solid
tumours (Awada et al, 2007). Interestingly, the combination
showed an increase of docetaxel AUC0–24 and Cmax in a dose-
independent manner. The most common side effect was derma-
tologic toxicity that led to a dose reduction or interruption of
sorafenib in 60% of patients. The authors suggest a dosing
schedule of docetaxel and sorafenib 400mg bid since cutaneous
toxicity is not a life-threatening side effect. In case of significant
dermatological toxicity, sorafenib dose should be reduced to
200mg bid. Such an approach should be evaluated in a phase II
study in HRPC.
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